LFA
NBIX icon

Legacy Financial Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Legacy Financial Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$210K Sell
1,246
-650
-34% -$96.4K 0.03% 416
2026
Q1 		$250K Buy
1,896
+293
+18% +$38.9K 0.03% 355
2025
Q4 		$227K Buy
+1,603
New +$232K 0.03% 362
2018
Q4 		– Sell
-540
Closed -$66K – 1030
2018
Q3 		$66K Buy
+540
New +$61.3K 0.02% 216

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Legacy Financial Advisors's NBIX Position: Q2 2026 in Review

Legacy Financial Advisors reduced its Neurocrine Biosciences (NBIX) stake by 34% in Q2 2026, selling an estimated $96.4K and leaving 1,246 shares worth $210K. The position accounts for 0.03% of the portfolio, ranked #416.

Legacy Financial Advisors first reported a position in NBIX in Q3 2018 and has held it in 4 quarters since. The position peaked at $250K in Q1 2026. 780 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Legacy Financial Advisors held 1,246 shares of Neurocrine Biosciences worth $210K as of Q2 2026.
  • Legacy Financial Advisors sold 650 Neurocrine Biosciences shares in Q2 2026, an estimated $96.4K.
  • Neurocrine Biosciences made up 0.03% of Legacy Financial Advisors's portfolio in Q2 2026, its #416 holding.
  • Legacy Financial Advisors first reported a position in Neurocrine Biosciences in Q3 2018 and has held it in 4 quarters since.
  • Legacy Financial Advisors's Neurocrine Biosciences position peaked at $250K in Q1 2026.
  • 780 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Legacy Financial Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.